Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2019


  • Products Id :- GMDHC11081IDB
  • |
  • Pages: 161
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Hospital Acquired Pneumonia (HAP)-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP)-Pipeline Review, H1 2019, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP)-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 5, 10, 10, 2 and 1 respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

Introduction

Hospital Acquired Pneumonia (HAP)-Overview

Hospital Acquired Pneumonia (HAP)-Therapeutics Development

Hospital Acquired Pneumonia (HAP)-Therapeutics Assessment

Hospital Acquired Pneumonia (HAP)-Companies Involved in Therapeutics Development

Hospital Acquired Pneumonia (HAP)-Drug Profiles

Hospital Acquired Pneumonia (HAP)-Dormant Projects

Hospital Acquired Pneumonia (HAP)-Discontinued Products

Hospital Acquired Pneumonia (HAP)-Product Development Milestones

Appendix

List of Figures

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

List of Tables

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Products under Development by Companies, H1 2019 (Contd..3), H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by Aridis Pharmaceuticals Inc, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by AstraZeneca Plc, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by Centauri Therapeutics Ltd, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by Cumberland Pharmaceuticals Inc, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by CytaCoat AB, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by Destiny Pharma Plc, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by Dong-A Socio Holdings Co Ltd, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by Evaxion Biotech ApS, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by MedImmune LLC, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by Meiji Seika Pharma Co Ltd, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by Merck & Co Inc, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by Motif Bio Plc, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by Nabriva Therapeutics Plc, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by Polyphor AG, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by Sealife PHARMA GMBH, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by Shionogi & Co Ltd, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by Spero Therapeutics Inc, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by Tetraphase Pharmaceuticals Inc, H1 2019

Hospital Acquired Pneumonia (HAP)-Pipeline by Wockhardt Ltd, H1 2019

Hospital Acquired Pneumonia (HAP)-Dormant Projects, H1 2019

Hospital Acquired Pneumonia (HAP)-Dormant Projects, H1 2019 (Contd..1), H1 2019

Hospital Acquired Pneumonia (HAP)-Discontinued Products, H1 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Aridis Pharmaceuticals Inc

AstraZeneca Plc

Centauri Therapeutics Ltd

Cumberland Pharmaceuticals Inc

CytaCoat AB

Destiny Pharma Plc

Dong-A Socio Holdings Co Ltd

Evaxion Biotech ApS

MedImmune LLC

Meiji Seika Pharma Co Ltd

Merck & Co Inc

Motif Bio Plc

Nabriva Therapeutics Plc

Polyphor AG

Sealife PHARMA GMBH

Shionogi & Co Ltd

Spero Therapeutics Inc

Tetraphase Pharmaceuticals Inc

Wockhardt Ltd

Hospital Acquired Pneumonia (HAP) Therapeutic Products under Development, Key Players in Hospital Acquired Pneumonia (HAP) Therapeutics, Hospital Acquired Pneumonia (HAP) Pipeline Overview, Hospital Acquired Pneumonia (HAP) Pipeline, Hospital Acquired Pneumonia (HAP) Pipeline Assessment

select a license
Single User License
USD 2000 INR 138000
Site License
USD 4000 INR 276000
Corporate User License
USD 6000 INR 414000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com